erplimackmd.bsky.social - Profile | ThreadSky | a Reddit-style client for Bluesky

How Trump’s Medical Research Cuts Would Hit Colleges and Hospitals in Every State www.nytimes.com/interactive/...

submitted 15 days ago • 0 comments

Exploring the burden of cancer in metastatic renal cell carcinoma (mRCC) 📊🧬 This study sheds light on the impact of mRCC on patients & healthcare systems. Don’t miss these key insights @ascocancer.bsky.social #GU25!

submitted 16 days ago • 0 comments

#MattGalsky updating results of #NIAGARA - great to see pathologic complete responses from neoadj gem-cis-durvalumab — durva improves disease free & overall survival even in those w pathCR. @ascocancer.bsky.social #GU25

submitted 17 days ago • 0 comments

On my way back home from #ascoGU25 Great discussion yesterday by @ERPlimackMD of #CheckMate 274 / #NIAGARA in the context of perioperative + adjuvant immunotherapy in #bladdercancer @oncodaily.bsky.social @oncoalert.bsky.social

submitted 16 days ago • 0 comments

Why is funding NIH so important? Listen to the Good News About Cancer w/ @charlesryanmd.bsky.social @mskcancercenter.bsky.social @drkarenknudsen.bsky.social & Dr. Morgans. Also amazing news about decline in lung cancer in Puerto Rico b/c of public health measures! podcasts.apple.com/us/podcast/4...

submitted 16 days ago • 0 comments

Comparison of Adjuvant regimens for cancer across tumor types #GU25. Nivolumab per Checkmate 274 for #bladdercancer rises to the top. docs.google.com/presentation...

submitted 16 days ago • 0 comments

Fantastic to see @IyerGopa showing updated data from FGFR3 inhibitor Loxo-435 with ORR of 41% DCR 90% 50% (6/12 patients) confirmed responses with prior FGFR3 inhibitor @MSKCancerCenter #ASCOGU #GU25

submitted 16 days ago • 0 comments

@erplimackmd.bsky.social with killer discussion setting the scene for the #NIAGARA “sandwich” & #Checkmate274, both practice changing for our pts w #bladdercancer. @ascocancer.bsky.social #GU25

submitted 17 days ago • 1 comment

Watching #BCR session @asco #GU25 it is very clear there is a drive to treat #BCR asap esp w/+ #PSMA But there is no data supporting a curative strategy & in that context deferring therapy max’ing #QOL is quite reasonable given JHU MFS data below ascopubs.org/doi/10.1200/...

submitted 17 days ago • 1 comment

Announcing the ASCO Genitourinary Cancers Symposium Featured Voices! Follow along for a range of expert insights and join the conversation using the official hashtag: #GU25 Not yet registered? There’s still time to join us in person or online: brnw.ch/21wQAYk

submitted 21 days ago • 0 comments

As @asco #GU25 approaches worth considering again the true value of Progression Free Survival (#PFS) endpoints in #ProstateCancer www.nature.com/articles/s41...

submitted 20 days ago • 0 comments

SUPER BOWL CHAMPIONS! THIS ONE’S FOR YOU PHILLY!

submitted 21 days ago • 512 comments

Trump & Musk are making massive cuts to the National Institutes of Health. I know there is a lot going on right now, but this is one of worst things they have done so far, will affect cancer research and trials, the search for cures, innovation and competitiveness, our universities. Your lives.

submitted 22 days ago • 509 comments

Both ERA Commons and NIH Reporter are currently unavailable.

submitted 22 days ago • 1 comment

🚨In <1 wk, it’s #GU25🚨 Let’s discuss the current SoC ➕ how the data will change/reinforce our practice at #AdvInOnc25: - Bladder Ca - Prostate Ca - RCC Join us LIVE 📅 Date: Feb 12, 2025 ⏰ Time: 6:00-8:00PM 📝 bit.ly/guaio25 #OncSky #MedSky #gusm #Oncology #Cancer #CanSky

submitted 24 days ago • 0 comments

In the ESOPEC trial, researchers evaluated whether perioperative chemotherapy improves overall survival as compared with preoperative chemoradiotherapy in patients with resectable esophageal adenocarcinoma. Full trial results and Plain Language Summary: nej.md/4apWlo5 #MedSky #Oncology

submitted 36 days ago • 0 comments

Hello, #MedSky community! We’re excited to begin our Bluesky journey. Here is a sampling of the trusted, influential, and essential information you can expect when you follow us:

submitted 87 days ago • 32 comments

FDA Grants Priority Review to Belzutifan for Advanced Pheochromocytoma and Paraganglioma @fda.gov #oncology www.onclive.com/view/fda-gra...

submitted 35 days ago • 0 comments

Hello out there scientists. If you're having meetings or grants or anything else impacted by freeze of NSF meetings, please feel free to reach out to me to share your story. Signal: thealexknapp.79 Email: [email protected]

submitted 35 days ago • 14 comments

🎉 EMA celebrates its 3️⃣0️⃣th anniversary highlighting its evolving role at the centre of the EU assessing & authorising safe, high-quality medicines for 450 million people & countless animals in Europe. Learn more about EMA’s key achievements over the past 30 years: www.ema.europa.eu/en/news/ema-...

submitted 35 days ago • 36 comments

This is huge. The European equivalent to the FDA has said enough to the propaganda machine X. Others will follow. #medsky #oncosky www.reuters.com/world/europe...

submitted 34 days ago • 3 comments

The clearest sign of intellectual chemistry isn’t agreeing with someone. It’s enjoying your disagreements with them. Harmony is not the combination of identical sounds. It’s the pleasing arrangement of different tones, voices, or instruments. Creative tension makes beautiful music.

submitted 36 days ago • 51 comments

Creating a bladder & kidney cancer starter pack of friends and colleagues here in @bsky.app! Please comment if you want to be added! bsky.app/start/did:pl... @pgrivasmdphd.bsky.social @drchoueiri.bsky.social @erplimackmd.bsky.social @davidaggen.bsky.social @pcvblack.bsky.social

submitted 39 days ago • 6 comments

Roughly 6,000 readers answered our poll, with many declaring that Bluesky was nicer, kinder and less antagonistic to science than X https://go.nature.com/42tH8Ai

submitted 38 days ago • 55 comments

Thanks Esther for this explainer, I hope it reaches the right audience. The complexity of health research is not widely appreciated, yet the diseases scientists are trying to cure affect us all.

submitted 37 days ago • 1 comment

Remembering Amy Babler: A fearless Advocate for Cancer Awareness and Communications @foxchasesurgonc.bsky.social oncodaily.com/blog/amy-bab... #Cancer #OncoDaily #Oncology #Medicine #Health

submitted 46 days ago • 0 comments

Thrilled to announce that my dear friend and colleague, Jay Simhan, MD, FACS, has been named Chair of Urology at Temple University Hospital! I’m thrilled to partner as two departments under the Fox Chase-Temple Urologic Institute to elevate our already world-class program to even greater heights!

submitted 58 days ago • 0 comments

This Christmas and every year I remember my current and past patients with ornaments on our tree. Have been fortunate to care for thousands in my ten year career in oncology. Hope to help thousands more in the years to come. 🎄🕯️

submitted 67 days ago • 0 comments

Can some MIBC patients safely skip cystectomy? In a phase II trial, 48% of biomarker-selected patients on active surveillance post-AMVAC avoided cystectomy without metastasis. 2-yr MFS: 73%. @oncoalert.bsky.social @oncbrothers.bsky.social @erplimackmd.bsky.social doi.org/10.1200/JCO-...

submitted 75 days ago • 1 comment

#PSMA imaging is showing #ProstateCancer in a WAY never seen before but it is unlikely to be showing Prostate Cancer that we have never encountered before The presumption of the latter leads to aggressive therapy which may not be required More data on this coming from @theNCI

submitted 83 days ago • 0 comments

Another memorable night. #SUO24 reunion (credit @urocorrea.bsky.social ) bringing together the extended FCCC family, and introducing future YUO/SUO colleagues. To alums who couldn’t make it, we hope to see you #AUA25 in Vegas, baby!

submitted 86 days ago • 0 comments

Percentage of available positions that filled in yesterday’s fellowship match.

submitted 88 days ago • 13 comments

Stayed active during 17-hour flight from SEA->Singapore :-) Looking forward to present TROPiCS04 phase 3 trial data at #ESMOASIA on Dec 7 ~10am local time discussed by Dr. Friedlander @oncoalert.bsky.social @achoud72.bsky.social @erplimackmd.bsky.social @valdesan.bsky.social @fredhutch.bsky.social

submitted 87 days ago • 1 comment

🥳🥳🥳 The final results of the 2024 #HCWvsHunger competition have been confirmed & certified! Most exciting: #MedTwitter & supporters have raised a total of $3,155,425 to fight #FoodInsecurity since the first annual competition in 12/20!! /1 cc @tmprowell.bsky.social @shematologist.bsky.social

submitted 88 days ago • 2 comments

Q&A—how to apply ctDNA in medical management—differing approaches by the panel reflects lack of existing data on whether ready for prime time and if it shld lead to a change in care compared to using clinical/path alone. #blcsm #SUO24

submitted 89 days ago • 0 comments

Join the conversation on all things #bladdercancer #kidneycancer #prostatecancer and help grow the GU Oncology Starter Pack go.bsky.app/6NdMXmY

submitted 101 days ago • 7 comments

De-escalation (of numbers of drugs as well as dosages) is shaping up to be a major theme in #oncology, beginning with @sabcs.bsky.social coming up next month. Colleagues in #breastcancer leading the way, maybe more to come for GI cancers at #GI25, and even more at #ASCO25?

submitted 98 days ago • 0 comments

ASCO annual meeting 2025 abstract submitter open - closes Jan 28th. To support global innovation in cancer research, payment waivers offered to 1st authors from low- & lower-middle-income countries (World Bank)! Apply for a waiver when you submit an abstract conferences.asco.org/am/abstract-...

submitted 100 days ago • 2 comments

ICYMI: 30 year outcomes from SPCG-4 dx.doi.org/10.1056/NEJM... RP vs. WW for clinically detected #prostatecancer reduces CSM 48% and ACM by 26%. NNT down to 6. Clear benefit to treatment of clinically detectable disease if (and only if) your pt has a very long life expectancy. #pcsm

submitted 100 days ago • 1 comment

GU starter pack… started! Let me know if you want to be added. go.bsky.app/DtoXvaD #Genitourinary #Oncology #GUonc #ProstateCancer #KidneyCancer #Urothelial #BladderCancer #PenileCancer #TesticularCancer #pcsm #kcsm #blcsm #tcsm #Medsky #Medtwitter

submitted 107 days ago • 36 comments

I’m going to the Nobel prize celebrations in Stockholm in 2 weeks along w/100 other Rosetta contributors. I figure a few things we contributed were helpful in making it work in the pre-RF-diffusion days. Backbone-dependent scoring/sampling of rotamers helped design work, I think. Just got a new tux!

submitted 100 days ago • 8 comments

Join the conversation on all things #bladdercancer #kidneycancer #prostatecancer and help grow the GU Oncology Starter Pack go.bsky.app/6NdMXmY

submitted 101 days ago • 7 comments

Old Twitter” refers to the platform’s earlier role as a hub where scientists could talk to one another, distribute and discuss preprints and published papers and communicate their research to the public. @tmprowell.bsky.social @erikahamilton9.bsky.social www.science.org/content/arti...

submitted 102 days ago • 1 comment

Team lunch at Fox Chase 🙌 @dytcmd.bsky.social, you missed this one! @urocroll.bsky.social, nice hat!

submitted 102 days ago • 3 comments

Active surveillance for intermediate-risk prostate cancer rose from 5% in 2010 to 12.3% in 2020. Most common in GG1 cases (53.8% by 2020). PSA and GG remain key factors. #ProstateCancer #ActiveSurveillance #Oncology #CancerResearch @oncoalert.bsky.social

submitted 102 days ago • 1 comment